Roche has unveiled new Phase 3 data indicating that Xofluza (baloxavir marboxil) was well-tolerated and of comparable efficacy to its other therapy Tamiflu (oseltamivir) in the reduction of the duration of the symptoms of flu, including fever, in otherwise healthy child patients between the ages of one and 12.
Flu is very common in this patient population, with one in three children developing the disease every year, with symptoms often persisting longer than in adult patients.
